Évaluation de la réponse: critères cliniques, critères biologiques

摘要

In these last years of revolutionary tyrosine kinase inhibitor treatments, patients with chronic myeloid leukemia are most commonly monitored by regular examination of bone marrow and peripheral blood in order to assess the quality of the response to treatment. Biological criteria and adapted methodologies in cytogenetics and molecular biology have been established from clinical trials. To date, it is essential to know these criteria for an optimal therapeutic management of these patients, in order to guarantee a better overall survival and an event-free survival.